Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

WuXi PharmaTech Marks Second Quarter Of Earnings Rebound Following 2008's Devastating Loss, Opens New Drug Safety Testing Center

This article was originally published in PharmAsia News

Executive Summary

BEIJING - After recording a massive loss for 2008, WuXi PharmaTech, China's leading pharmaceutical contract research organization, posted a second consecutive quarter of earnings growth in the April-June period of this year
Advertisement

Related Content

WuXi Apptec Plots Future, But Is It Overreaching?
WuXi Apptec Plots Future, But Is It Overreaching?
Business And Finance In Brief
Business And Finance In Brief
Earnings Call Snapshots: Vanda, Jazz, WuXi, Lundbeck
Earnings Call Snapshots: Vanda, Jazz, WuXi, Lundbeck
Hit By U.S. Economic Tremors, Collapse In Biologics Business, WuXi PharmaTech Posts Massive Loss For 2008, American Unit AppTec Deeply Devalued
Hit By U.S. Economic Tremors, Collapse In Biologics Business, WuXi PharmaTech Posts Massive Loss For 2008, American Unit AppTec Deeply Devalued
Covance, WuXi Abandon Plans To Create Joint Drug Testing Facility In China
Advertisement
UsernamePublicRestriction

Register

SC072485

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel